Journal article
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status
Translational psychiatry, Vol.11(1), pp.585-585
11/13/2021
DOI: 10.1038/s41398-021-01709-9
PMCID: PMC8590691
PMID: 34775468
Abstract
Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer's pathology in the brain. A total of 1189 participants with plasma p-tau181 and PET data of amyloid, tau or FDG PET were included from ADNI. Cross-sectional relationships of plasma p-tau181 with PET biomarkers were tested. Longitudinally, we further investigated whether different p-tau181 levels at baseline predicted different progression of Alzheimer's pathological changes in the brain. We found plasma p-tau181 significantly correlated with brain amyloid (Spearman ρ = 0.45, P < 0.0001), tau (0.25, P = 0.0003), and FDG PET uptakes (-0.37, P < 0.0001), and increased along the Alzheimer's continuum. Individually, plasma p-tau181 could detect abnormal amyloid, tau pathologies and hypometabolism in the brain, similar with or even better than clinical indicators. The diagnostic accuracy of plasma p-tau181 elevated significantly when combined with clinical information (AUC = 0.814 for amyloid PET, 0.773 for tau PET, and 0.708 for FDG PET). Relationships of plasma p-tau181 with brain pathologies were partly or entirely mediated by the corresponding CSF biomarkers. Besides, individuals with abnormal plasma p-tau181 level (>18.85 pg/ml) at baseline had a higher risk of pathological progression in brain amyloid (HR: 2.32, 95%CI 1.32-4.08) and FDG PET (3.21, 95%CI 2.06-5.01) status. Plasma p-tau181 may be a sensitive screening test for detecting brain pathologies, and serve as a predictive biomarker for Alzheimer's pathophysiology.
Details
- Title: Subtitle
- Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status
- Creators
- Xue-Ning Shen - Huashan HospitalYu-Yuan Huang - Huashan HospitalShi-Dong Chen - Huashan HospitalYu Guo - Qingdao Municipal HospitalLan Tan - Qingdao Municipal HospitalQiang Dong - Huashan HospitalJin-Tai Yu - Shanghai Medical College of Fudan UniversityAlzheimer’s Disease Neuroimaging Initiative
- Contributors
- Del D Miller (Contributor) - University of Iowa, Psychiatry
- Resource Type
- Journal article
- Publication Details
- Translational psychiatry, Vol.11(1), pp.585-585
- DOI
- 10.1038/s41398-021-01709-9
- PMID
- 34775468
- PMCID
- PMC8590691
- NLM abbreviation
- Transl Psychiatry
- ISSN
- 2158-3188
- eISSN
- 2158-3188
- Grant note
- P30 AG066512 / NIA NIH HHS
- Language
- English
- Date published
- 11/13/2021
- Academic Unit
- Psychiatry
- Record Identifier
- 9984280831602771
Metrics
9 Record Views